Prafulla C Gokhale Selected Research

Oligonucleotides

1/2007	Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
3/2006	Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells.
5/2004	Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Prafulla C Gokhale Research Topics

Disease

41	Neoplasms (Cancer) 10/2022 - 11/2002
8	Lung Neoplasms (Lung Cancer) 01/2022 - 05/2011
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2020
3	Merkel Cell Carcinoma 10/2022 - 01/2020
3	Carcinoma (Carcinomatosis) 11/2021 - 05/2004
3	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 02/2016
3	Breast Neoplasms (Breast Cancer) 01/2007 - 05/2004
2	Malignant Mesothelioma 01/2021 - 12/2020
2	Rhabdoid Tumor (Rhabdoid Tumors) 01/2020 - 01/2019
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2018 - 12/2017
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2012 - 03/2004
1	Neuroendocrine Carcinoma 10/2022
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 10/2022
1	Edema (Dropsy) 01/2021
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2021
1	Brain Neoplasms (Brain Tumor) 01/2021
1	Glioma (Gliomas) 01/2021
1	Sarcoma (Soft Tissue Sarcoma) 03/2020
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2020
1	Skin Neoplasms (Skin Cancer) 01/2020
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020
1	Medullary Carcinoma 12/2019
1	Systemic Mastocytosis 11/2019
1	Medulloblastoma 01/2019
1	Myeloid Leukemia (Leukemia, Myelocytic) 12/2018

Drug/Important Bio-Agent (IBA)

10	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2002
8	Antisense OligonucleotidesIBA 01/2009 - 03/2004
7	LErafAONIBA 01/2009 - 11/2002
6	Phosphotransferases (Kinase)IBA 01/2022 - 03/2011
6	Pharmaceutical PreparationsIBA 01/2020 - 03/2004
5	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2020
4	ErbB Receptors (EGF Receptor)IBA 01/2022 - 01/2020
4	Liposomes (Liposome)IBA 01/2009 - 03/2004
3	Messenger RNA (mRNA)IBA 09/2021 - 03/2006
3	Immune Checkpoint InhibitorsIBA 01/2021 - 02/2016
3	Mechanistic Target of Rapamycin Complex 1IBA 01/2021 - 03/2011
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 05/2011
3	Small Interfering RNA (siRNA)IBA 01/2019 - 01/2009
3	OligonucleotidesIBA 01/2007 - 05/2004
2	Tumor Viral Antigens (Large T Antigen)IBA 01/2022 - 01/2020
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2022 - 01/2020
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 02/2006
2	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2021
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 01/2021
2	Biological ProductsIBA 03/2020 - 01/2019
2	UbiquitinIBA 01/2020 - 12/2017
2	Therapeutic UsesIBA 01/2019 - 05/2004
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 12/2018 - 01/2009
2	Antineoplastic Agents (Antineoplastics)IBA 08/2011 - 10/2010
2	Mechanistic Target of Rapamycin Complex 2IBA 08/2011 - 03/2011
2	Sirolimus (Rapamycin)FDA Link 08/2011 - 11/2006
2	3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA 05/2011 - 10/2010
1	Polycomb Repressive Complex 2IBA 10/2022
1	capmatinibIBA 01/2022
1	Protein Isoforms (Isoforms)IBA 01/2022
1	merestinibIBA 01/2022
1	QuinazolinonesIBA 01/2022
1	Viral ProteinsIBA 01/2022
1	milademetanIBA 01/2022
1	PanobinostatIBA 11/2021
1	Histone Deacetylase InhibitorsIBA 11/2021
1	abemaciclibIBA 01/2021
1	ChromatinIBA 01/2021
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021
1	LY3214996IBA 01/2021
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2021
1	LY3023414IBA 01/2021
1	Natural Killer Cell ReceptorsIBA 01/2021
1	Histone DemethylasesIBA 01/2021
1	Adenosine Triphosphate (ATP)IBA 01/2021
1	Atovaquone (Mepron)FDA Link 12/2020
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 12/2020
1	Immunoconjugates (Immunoconjugate)IBA 03/2020
1	monomethyl auristatin EIBA 03/2020
1	HomoharringtonineIBA 01/2020
1	Oncogene Proteins (Oncogene Protein)IBA 01/2020
1	Ligases (Synthetase)IBA 01/2020
1	NEO2734IBA 01/2020
1	Ubiquitin-Conjugating EnzymesIBA 12/2019
1	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2019
1	Proteasome InhibitorsIBA 12/2019
1	Sorafenib (BAY 43-9006)FDA Link 11/2019
1	midostaurinIBA 11/2019
1	tyrosine receptor (receptor, tyrosine)IBA 11/2019
1	quizartinibIBA 11/2019
1	crenolanibIBA 11/2019
1	avapritinibIBA 11/2019
1	gilteritinibIBA 11/2019
1	MicroRNAs (MicroRNA)IBA 01/2019
1	ATSP-7041IBA 01/2019
1	Histones (Histone)IBA 01/2019
1	RG7388IBA 01/2019
1	Small Molecule LibrariesIBA 01/2019
1	CytokinesIBA 01/2018
1	Ubiquitin CIBA 12/2017
1	LigandsIBA 02/2016

Therapy/Procedure

12	Therapeutics 01/2022 - 01/2007
3	Immunotherapy 01/2021 - 01/2021
2	Radiotherapy 01/2021 - 02/2006
2	Drug Therapy (Chemotherapy) 01/2020 - 03/2004